Skip to main content
SpringerLink
Log in

Immunogénicité et tolérance

  • Chapter
Traité des infections et pathologies génitales à papillomavirus

  • 441 Accesses

Abstrait

Les résultats de tolérance et d’immunogénicité obtenus avec les vaccins anti-papillomavirus composés de pseudo-particules virales sont très encourageants. Les anticorps persistent pendant 4 à 5 ans à un titre au moins supérieur à celui observé lors d’une infection naturelle. Cependant, des questions sont encore en suspens, comme la durée de la protection et la nécessité d’injections de rappel au-delà de 5 ans, ou le titre en anticorps anti-HPV protectif. Cette vaccination devrait conduire en quelques décennies à une réduction significative des cancers du col de l’utérus et à plus court terme à une réduction des traitements du fait d’une réduction importante des lésions précancéreuses.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Walboomers JM, Jacobs MV, Manos MM et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12–9

    Article  PubMed  CAS  Google Scholar 

  2. Munoz N, Bosch FX, de Sanjose S et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518–27

    Article  PubMed  Google Scholar 

  3. Khan MJ, Castle PE, Lorincz AT et al. (2005) The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97: 1072–9

    Article  PubMed  Google Scholar 

  4. Cates W Jr (1999) Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis. (4Suppl): S2–7

    Google Scholar 

  5. Ho GY, Bierman R, Beardsley L et al. (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338: 423–8

    Article  PubMed  CAS  Google Scholar 

  6. Woodman CB, Collins S, Winter H et al. (2001) Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357: 1831–6

    Article  PubMed  CAS  Google Scholar 

  7. Brisson J, Bairati I, Morin C et al. (1996) Determinants of persistent detection of human papillomavirus DNA in the uterine cervix. J Infect Dis 173: 794–9

    PubMed  CAS  Google Scholar 

  8. Molano M, Van den Brule A, Plummer M et al. (2003) Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 158: 486–94

    Article  PubMed  Google Scholar 

  9. Rose RC, Bonnez W, Reichman RC, Garcea RL (1993) Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 67: 1936–44

    PubMed  CAS  Google Scholar 

  10. Kirnbauer R, Taub J, Greenstone H et al. (1993) Efficient self-assembly of human papillomavirus type 16 L1 and L1–L2 into virus-like particles. J Virol 67: 6929–36

    PubMed  CAS  Google Scholar 

  11. Bell JA, Sundberg JP, Ghim SJ (1994) A formalin-inactivated vaccine protects against mucosal papilomavirus infection: a canine model. Pathobiology 62: 194–8

    PubMed  CAS  Google Scholar 

  12. Breitburd F, Kirnbauer R, Hubbert NL et al. (1995) Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69: 3959–63

    PubMed  CAS  Google Scholar 

  13. Suzich JA, Ghim SJ, Palmer-Hill F et al. (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomavirus. Proc Natl Acad Sci USA 92: 11553–7

    Article  PubMed  CAS  Google Scholar 

  14. Kirnbauer R, Chandrachud LM, O’Neil BW et al. (1996) Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219: 37–44

    Article  PubMed  CAS  Google Scholar 

  15. Christensen ND, Reed CA, Cladel NM et al. (1996) Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70: 960–5

    PubMed  CAS  Google Scholar 

  16. Breitburd F, Coursaget P (1999) Human papillomavirus vaccines. Seminars in Cancer Biology 9: 431–44

    Article  PubMed  CAS  Google Scholar 

  17. Rose RC, Reichman RC, Bonnez W (1994) Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 75: 2075–9

    Article  PubMed  Google Scholar 

  18. Christensen ND, Dillner J, Eklund C et al. (1996) Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223: 174–84

    Article  PubMed  CAS  Google Scholar 

  19. Christensen ND, Reed CA, Cladel NM (1996) Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 15: 477–86

    Article  Google Scholar 

  20. Fleury MJ, Touze A, Alvarez E et al. (2006) Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31. Arch Virol 151: 1511–23

    Article  PubMed  CAS  Google Scholar 

  21. Villa LL, Costa RL, Petta CA et al. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6: 271–8

    Article  PubMed  Google Scholar 

  22. Villa LL, Ault KA, Giuliano AR et al. (2006) Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24: 5571–83

    Article  PubMed  CAS  Google Scholar 

  23. Harper DM, Franco EL, Wheeler C et al. (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364: 1757–65

    Article  PubMed  CAS  Google Scholar 

  24. Harper DM, Franco EL, Wheeler C et al. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367: 1247–55

    Article  PubMed  CAS  Google Scholar 

  25. Harro CD, Pang YY, Roden RB et al. (2001) Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 93: 284–92

    Article  PubMed  CAS  Google Scholar 

  26. Fife KH, Wheeler CM, Koutsky LA et al. (2004) Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine 22: 2943–52

    Article  PubMed  CAS  Google Scholar 

  27. Mao C, Koutsky LA, Ault KA et al. (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107: 18–27

    PubMed  Google Scholar 

  28. Bousarghin L, Combita AL, Touzé A (2002) Immunization with HPV L1 VLPs induced cross-neutralizing antibodies. 20th International Papillomavirus Conference, Paris, 2002; O100, p. 98

    Google Scholar 

  29. Buck CB, Pastrana DV, Lowy DR, Schiller JT (2005) Generation of HPV pseudo-virions using transfection and their use in neutralization assays. Methods Mol Med 119: 445–62

    PubMed  CAS  Google Scholar 

  30. Dubin G (2005) Enhanced Immunogenicity of a Candidate Human Papillomavirus (HPV) 16/18 L1 Virus Like Particle (VLP) Vaccine With Novel AS04 Adjuvant in Pre-Teens/Adolescents. Proc. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2005, Washington (USA)

    Google Scholar 

  31. Schwarz TF (2006) An ASO4-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15–55 years old. J Clin Oncol 24(Suppl): 50s Abstr. 1008. ASCO 2006

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. équipe « vectorisation, virus, vaccins », laboratoire membre de l’IFR 136 Agents transmissibles et infectiologie, Faculté de Pharmacie Ph. Maupas, INSERM U618, 31 avenue Monge, 37200, Tours

    P. Coursaget, A. Touzé, L. Bousarghin & M. Fleury

Authors
  1. P. Coursaget
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Touzé
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Bousarghin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Fleury
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Coursaget, P., Touzé, A., Bousarghin, L., Fleury, M. (2007). Immunogénicité et tolérance. In: Traité des infections et pathologies génitales à papillomavirus. Springer, Paris. https://doi.org/10.1007/978-2-287-72066-6_54

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-72066-6_54

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-72064-2

  • Online ISBN: 978-2-287-72066-6

Publish with us

Policies and ethics

Search

Navigation